SCHEMBL31024321

SCHEMBL31024321

CN(C)CCc1c[nH]c2cccc(OC(=O)CCCNC(=O)C(C)(C)C)c12

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HTR2A P28223 9/20 0.61
▸ HTR6 P50406 2/20 0.54
▸ HTR1A P08908 5/20 0.53
▸ HTR2C P28335 4/20 0.53
▸ HTR2B P41595 4/20 0.53
▸ HTR1B P28222 4/20 0.47
▸ HTR1D P28221 3/20 0.47
▸ DRD1 P21728 1/20 0.47
▸ HTR1E P28566 1/20 0.47
▸ ADORA2A P29274 1/20 0.47
▸ ADORA2B P29275 1/20 0.47
▸ HTR7 P34969 1/20 0.47
▸ DRD3 P35462 1/20 0.47
▸ HTR5A P47898 1/20 0.47
▸ MTNR1A P48039 1/20 0.47
▸ MTNR1B P49286 1/20 0.47
▸ HTR1F P30939 1/20 0.46
▸ SLC6A4 P31645 1/20 0.41
▸ SLC6A2 P23975 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31024311 0.89 HTR2A (0.64) HTR2AHTR6HTR1AHTR2CHTR2B
SCHEMBL25790565 0.87 HTR2A (0.76) HTR2AHTR6HTR1AHTR2CHTR2B
SCHEMBL25790684 0.87 HTR2A (0.73) HTR2AHTR6HTR1AHTR2CHTR2B
Hydrochloric Acid SCHEMBL31634311 0.86 HTR2A (0.71) HTR2AHTR6HTR1AHTR2CHTR2B
SCHEMBL25792493 0.86 HTR2A (0.78) HTR2AHTR6HTR1AHTR2CHTR2B
SCHEMBL25790560 0.86 HTR2A (0.78) HTR2AHTR6HTR1AHTR2CHTR2B
SCHEMBL27219351 0.84 HTR6 (0.70) HTR2AHTR6HTR1AHTR2CHTR2B
SCHEMBL31320737 0.84 HTR2A (0.67) HTR2AHTR6HTR1AHTR2CHTR2B
SCHEMBL24994140 0.84 HTR2A (0.78) HTR2AHTR6HTR1AHTR2CHTR2B
SCHEMBL31417453 0.83 HTR2A (0.66) HTR2AHTR6HTR1AHTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4655282-A1 3-(2-(DIMETHYLAMINO)ETHYL)-1H-INDOL-4-YL DERIVATIVES COMPASS Pathfinder Limited (GB) 2025-12-03 — — EP disclosed
US-20240269113-A1 3-(2-(DIMETHYLAMINO)ETHYL)-1H-INDOL-4-yl DERIVATIVES COMPASS PATHFINDER LIMITED (GB) 2024-08-15 — — US disclosed
WO-2024156732-A1 3-(2-(DIMETHYLAMINO)ETHYL)-1H-INDOL-4-YL DERIVATIVES COMPASS PATHFINDER LIMITED (GB) 2024-08-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240269113-A1 3-(2-(DIMETHYLAMINO)ETHYL)-1H-INDOL-4-yl DERIVATIVES HTR2C, HTR2A, HTR1A HTR2A 2/4885HTR6 6/4885HTR1A 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback